1-methyl-d-tryptophan

DRUG5 trials

Sponsors

National Cancer Institute (NCI), NewLink Genetics Corporation, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Breast CancerLung CancerMale Breast CancerMelanomaPancreatic CancerRecurrent Breast CancerSolid TumorsStage IV Breast Cancer

Phase 1

1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

CompletedNCT00567931

National Cancer Institute (NCI)Unspecified Adult Solid Tumor, Protocol Specific

Start: 2007-10-31End: 2012-09-30Updated: 2014-07-24

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors

TerminatedNCT00739609

NewLink Genetics CorporationBreast Cancer, Lung Cancer, Melanoma +2

Start: 2008-08-31End: 2012-10-31Updated: 2020-05-28

Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer

CompletedNCT01042535

H. Lee Moffitt Cancer Center and Research InstituteMale Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer +1

Start: 2009-12-28End: 2018-02-27Updated: 2018-04-11

1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors

CompletedNCT01191216

National Cancer Institute (NCI)Unspecified Adult Solid Tumor, Protocol Specific

Start: 2010-09-30End: 2013-08-31Updated: 2014-07-24

Unknown Phase

C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer

WithdrawnNCT01302821

H. Lee Moffitt Cancer Center and Research InstituteBreast Cancer

Start: 2013-01-31End: 2014-12-31Updated: 2017-02-23

Related Papers

Abstract P2-11-09: A phase 2 randomized trial of the IDO pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: Preliminary data

Cancer Research2016-02-156 citations

A phase 2 study of Ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors.

Journal of Clinical Oncology2014-05-203 citations